Pharmaceutical Factory Inside Human Body

FDA Under Trump: Navigating New Drug Approvals & Industry Ties

Lena Voss monogram
Lena Voss in Health & Wellness October 2026 • 4 min read.

"Decoding Scott Gottlieb's nomination and Europe's chemistry patent surge"


The pharmaceutical landscape is constantly evolving, influenced by political decisions, regulatory changes, and scientific advancements. Two significant developments recently caught the attention of industry experts and the public: President Donald Trump's nomination of Scott Gottlieb to head the Food and Drug Administration (FDA) and the remarkable surge in chemistry-related patents in Europe.

Scott Gottlieb's nomination sparked mixed reactions due to his extensive ties to the pharmaceutical industry, raising questions about potential conflicts of interest. Simultaneously, Europe witnessed an unprecedented increase in chemistry-related patents, signaling a vibrant and innovative environment for chemical and pharmaceutical research.

In this article, we delve into these two critical events, examining their potential impact on drug approvals, healthcare innovation, and the broader pharmaceutical industry. Understanding these dynamics is crucial for anyone interested in healthcare, pharmaceuticals, and the ever-changing landscape of scientific innovation.

AI Search Multiple angles on this topic

Gottlieb’s FDA Ties

Scott Gottlieb led the FDA during Donald Trump’s first presidency and later opposed Robert F. Kennedy Jr.’s nomination for health secretary. KFF Health News reported that Trump’s 2017 choice for FDA commissioner had longstanding ties to pharmaceutical companies as a board member or consultant. The report also said Gottlieb had to recuse himself multiple times while working at the FDA.

Draft Guidance and Standards

FDA’s draft guidance on new approach methodologies addresses their use in drug development. The 2026 draft states that, once finalized, it will represent the agency’s current thinking but will not establish rights or bind FDA or the public. A 2019 statement from FDA Commissioner Scott Gottlieb said that, after a standard is recognized, applicants generally would not need to validate the approach described in that standard and could instead focus on using the method appropriately and meeting acceptance criteria.

Gottlieb’s FDA Tenure

Scott Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. Stanford Medicine identifies him as a Special Partner on New Enterprise Associates Inc.’s healthcare investment team. His FDA leadership is therefore part of a career that also included healthcare investment work.

Scott Gottlieb: Balancing Industry Ties and Public Trust at the FDA

Pharmaceutical Factory Inside Human Body

President Donald Trump's decision to nominate Scott Gottlieb as the FDA commissioner was met with both enthusiasm and apprehension. Gottlieb, a physician with prior experience at the FDA, is seen as a proponent of faster drug approvals, particularly for low-cost generics. This aligns with the Trump administration's goal of reducing healthcare costs and increasing access to medications.

However, Gottlieb's deep connections to the pharmaceutical industry have raised concerns about potential conflicts of interest. He has served on the boards of several pharmaceutical companies and has worked as a consultant for others. Critics argue that these ties could influence his decisions as FDA commissioner, potentially prioritizing industry interests over public health.

  • Potential Benefits: Expedited drug approvals, increased availability of generic medications, reduced healthcare costs.
  • Potential Risks: Conflicts of interest, compromised safety standards, prioritization of industry profits over public health.
  • Expert Opinions: Industry leaders welcomed Gottlieb's nomination, citing his experience and understanding of the pharmaceutical landscape. Public health advocates expressed concerns about his industry ties and potential impact on drug safety and affordability.
AI Search Multiple angles on this topic

User Fees and Generic Entry

The FDA’s FY 2018 PDUFA performance report explains that the Prescription Drug User Fee Act was enacted in 1992. PDUFA authorized FDA to collect fees from pharmaceutical and biotechnology companies for reviewing certain human drug and biological products. A USPTO-FDA study identifies the launch date, if any, of the first generic version of a drug product that had launched by September 18, 2023.

Concerns About Influence

A Stanford Law Review source argues that FDA work cannot be meaningfully detached from value-laden decisions. Public Citizen reported that Gottlieb favored getting medications to market faster, even if that required accepting greater uncertainty about safety and efficacy at approval. Separately, a Union of Concerned Scientists survey found that 45% of FDA scientists viewed political-interest consideration as too high, while 33% said the same about business interests; one-third agreed that agency practices deferring to business interests had harmed the FDA.

2018 Review Performance

FDA’s 2018 New Drug report states that CDER approved 56 of 59 novel drugs that year, or 95%, on the first review cycle. A first-cycle approval meant the application did not receive a complete response letter requiring resubmission with additional information. FDA records identify Scott Gottlieb as the 23rd Commissioner of Food and Drugs from May 11, 2017, to April 5, 2019, while AEI likewise describes him as commissioner from 2017 to 2019.

Gottlieb's supporters argue that his industry experience provides him with valuable insights into the challenges and opportunities facing the pharmaceutical sector. They believe that he can effectively navigate the complex regulatory landscape while promoting innovation and ensuring patient safety. Ultimately, Gottlieb's success as FDA commissioner will depend on his ability to balance these competing interests and prioritize the well-being of the American public.

Looking Ahead: Innovation and Regulation in the Pharmaceutical Industry

The future of the pharmaceutical industry hinges on striking a delicate balance between fostering innovation and ensuring patient safety. As new technologies and treatments emerge, regulatory bodies like the FDA must adapt to keep pace while upholding rigorous standards. The developments discussed in this article – Scott Gottlieb's FDA nomination and the surge in European chemistry patents – highlight the complexities and challenges involved in this ongoing process. By understanding these dynamics, we can work towards a healthcare system that promotes innovation, affordability, and, above all, the well-being of patients.

AI Search Multiple angles on this topic

A Continuing Regulatory Debate

Scott Gottlieb announced his resignation as FDA commissioner on March 5, 2019. The Washington Post described the regulatory path for approving and recommending new vaccines through FDA and the CDC as being stymied in a February 2026 opinion. The New York Times identifies Gottlieb as a senior fellow at AEI and notes that he served as FDA commissioner from May 2017 to April 2019.

Innovation and Rare Diseases

Recent discussions involving Scott Gottlieb focus on FDA innovation, new agency leadership, and the future of healthcare regulation and biotechnology. CNBC reported that Gottlieb discussed the FDA’s new framework for accelerating individualized therapies for rare genetic diseases on March 27, 2026. WWSG also described his commentary as covering drug development, biopharma trends, tariffs, and supply-chain disruption.

What FDA approval figures measure

  • 89.3%; 45.3% of 448 pivotal trialsAmong 448 pivotal trials considered across FDA approvals from 2005 to 2012, 89.3% were randomized controlled trials and 45.3% used surrogate endpoints.[1]
  • 8.6 versus 12.1 months of average review timeMarketing applications using at least one expedited program had an average FDA review time of 8.6 months, compared with 12.1 months for applications without one.[2]

What the approval evidence adds up to

These figures show that approval evidence can rely on different kinds of trial endpoints, and that many pivotal trials in the period used surrogate measures rather than clinical outcomes. The figures describe evidence used at approval; they do not by themselves establish how well those measures predict outcomes for patients.[1] [3] [4]

FDA review was faster on average for applications involving an expedited program than for those without one. That comparison concerns review duration, not the effects of those programs on patient outcomes.[2]

The FDA’s task involves balancing the quality of clinical evidence before approval with timely access to promising drugs and continued evaluation afterward.[3]

What remains uncertain about approval evidence

  • How often do surrogate markers that support approval ultimately predict patient-relevant outcomes such as mortality or morbidity? The cited evidence describes their use and notes that correlations with overall survival can be weak or unknown.[4] [5]

Sources

  1. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018 (pmc.ncbi.nlm.nih.gov)
  2. GAO-16-192, Drug Safety: FDA Expedites Many Applications, But Data for Postapproval Oversight Need Improvement (www.gao.gov)
  3. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review (pmc.ncbi.nlm.nih.gov)
  4. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study (pmc.ncbi.nlm.nih.gov)
  5. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019 (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

Who is Scott Gottlieb and what are the potential benefits and risks associated with his nomination as FDA commissioner?

Scott Gottlieb's nomination as FDA commissioner under President Trump aimed to speed up drug approvals, particularly for generics, to lower healthcare costs. However, his extensive ties to the pharmaceutical industry raised concerns about potential conflicts of interest. The implications include faster access to medications but also the risk of compromised safety standards if industry interests are prioritized over public health. Balancing these competing interests is crucial for ensuring both innovation and patient safety. Notably, the FDA's role in regulating drug advertising and promotion, though not explicitly mentioned, is also vital to consider in this context.

2

Why is there a surge in chemistry-related patents in Europe?

Chemistry-related patents are important because they signify innovation and advancement in the pharmaceutical industry. A surge in these patents, like the one witnessed in Europe, suggests a dynamic environment for chemical and pharmaceutical research. This can lead to the development of new drugs, treatments, and technologies. The implications are significant for healthcare innovation and the broader pharmaceutical industry. Increased patent activity can stimulate economic growth and improve patient outcomes. This trend also affects the global competitiveness of different regions in pharmaceutical research and development.

3

What are potential conflicts of interest, and how could they affect the FDA?

Potential conflicts of interest arise when an individual's personal or professional interests could influence their decisions in a way that compromises their objectivity and integrity. In the context of Scott Gottlieb's nomination, his ties to the pharmaceutical industry raised concerns that his decisions as FDA commissioner might favor industry interests over public health. The implications of such conflicts could include biased drug approvals, compromised safety standards, and a prioritization of industry profits over patient well-being. Addressing and mitigating these conflicts is essential for maintaining public trust in regulatory bodies.

4

How does the FDA ensure patient safety in the pharmaceutical industry?

The FDA plays a vital role in ensuring patient safety by regulating the development, approval, and marketing of drugs and medical devices. The FDA sets rigorous standards for safety and efficacy, conducts inspections, and monitors adverse events. This is essential for protecting the public from harmful or ineffective products. Potential benefits of a well-functioning FDA include access to safe and effective treatments, reduced healthcare costs, and increased public trust in the pharmaceutical industry. The FDA's oversight extends to clinical trials, manufacturing processes, and post-market surveillance, all of which contribute to ensuring patient safety.

5

Why is innovation important in the pharmaceutical industry?

Innovation in the pharmaceutical industry is crucial for developing new and improved treatments for diseases and medical conditions. It involves discovering new drug targets, developing novel therapies, and improving existing medications. Fostering innovation requires investment in research and development, collaboration between industry and academia, and a supportive regulatory environment. The implications of innovation are far-reaching, including improved patient outcomes, reduced healthcare costs, and economic growth. Without continued innovation, the pharmaceutical industry would stagnate, and patients would miss out on potentially life-saving treatments.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.